Lilly antibody drug fails in COVID-19 study for hospitalized patients
U.S. government officials are putting an early end to a study testing an Eli Lilly and Co. antibody drug for people hospitalized with COVID-19 because it doesn’t seem to be helping them. The Indianapolis-based drugmaker, however, is continuing to back the treatment.